Skip to content

Efficiency of everolimus for the treatment of kidney transplanted patients presenting a missing self-induced NK-mediated rejection (STARR)

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-513814-37-00
Acronym
69HCL17_0706
Enrollment
20
Registered
2024-09-30
Start date
2020-12-03
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplantation

Brief summary

Relative variation in Glomerular Filtration Rate (GFR) estimated by the CKD-EPI method between D-15 and M6 after starting everolimus.

Detailed description

Histological: variation in the microvascular inflammation score (g+cpt) and chronic glomerular (cg) and vascular (cv) lesions determined according to the Banff 2013 classification between D-15 and M6, Biological: variation in the degree of in vitro activability of NK between D0 and M6, Clinical: relative variation in the proteinuria/creatininuria ratio between D-15 and M6

Interventions

DRUG25 mg
DRUG75 mg
DRUGcomprimé
DRUG1 mg
DRUG5 mg

Sponsors

Hospices Civils De Lyon
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Relative variation in Glomerular Filtration Rate (GFR) estimated by the CKD-EPI method between D-15 and M6 after starting everolimus.

Secondary

MeasureTime frame
Histological: variation in the microvascular inflammation score (g+cpt) and chronic glomerular (cg) and vascular (cv) lesions determined according to the Banff 2013 classification between D-15 and M6, Biological: variation in the degree of in vitro activability of NK between D0 and M6, Clinical: relative variation in the proteinuria/creatininuria ratio between D-15 and M6

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026